Systimmune Inc.
Clinical trials sponsored by Systimmune Inc., explained in plain language.
-
New drug candidate BL-M05D1 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:41 UTC
-
New hope for tough leukemia: experimental drug BL-M11D1 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called BL-M11D1 in 120 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the disease. Participants must …
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:39 UTC
-
New drug targets hard-to-treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-M07D1 in adults with advanced solid tumors that have the HER2 protein. The goal is to check safety, find the right dose, and see if it shrinks tumors. About 280 people with cancers like breast, lung, stomach, or ovarian cancer tha…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New drug BL-M14D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 120 participants wil…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New drug BL-B01D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 470 adults will take part.
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC